Your browser doesn't support javascript.
loading
A miRNA-7704/IL2RB/AKT feedback loop regulates tumorigenesis and chemoresistance in ovarian cancer.
Meng, Xuan; Liang, Xiaoqing; Yang, Shengjie; Wu, Dongsheng; Wang, Xinghe.
Affiliation
  • Meng X; Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China; Department of Oncology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.
  • Liang X; Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Yang S; Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Wu D; Department of Emergency, Yantaishan Hospital, Yantai, Shandong, China.
  • Wang X; Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. Electronic address: wangxh8575@163.com.
Exp Cell Res ; 437(2): 114012, 2024 Apr 15.
Article in En | MEDLINE | ID: mdl-38565343
ABSTRACT
Ovarian cancer is one of the most common gynecological tumors worldwide. Despite the availability of multiple treatments for ovarian cancer, its resistance to chemotherapy remains a significant challenge. miRNAs play crucial roles in the initiation and progression of cancer by affecting processes such as differentiation, proliferation, and chemoresistance. According to microarray and qPCR analyses, miR-7704 is significantly downregulated in cisplatin-resistant cells compared to parental cells. In this study, we found that miR-7704 inhibited the proliferation and promoted cisplatin sensitivity of ovarian cancer cells in vitro and in vivo. Moreover, ectopic expression of miR-7704 had the same effect as IL2RB knockdown. Further mechanistic studies revealed that miR-7704 played an inhibitory role by regulating IL2RB expression to inactivate the AKT signaling pathway. Furthermore, IL2RB reversed the miR-7704 mediated resistance to cisplatin in ovarian cancer. Based on these findings, miR-7704 and IL2RB show the potential as novel therapeutic targets for ovarian cancer.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / MicroRNAs Limits: Female / Humans Language: En Journal: Exp Cell Res Year: 2024 Document type: Article Affiliation country: China Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / MicroRNAs Limits: Female / Humans Language: En Journal: Exp Cell Res Year: 2024 Document type: Article Affiliation country: China Country of publication: United States